Powder: -20°C for 3 years | In solvent: -80°C for 1 year
S18-000003 is an effective orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t inhibitor (IC50: 29 nM). S18-000003 inhibits IL-17 production.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 87.00 | |
5 mg | In stock | $ 213.00 | |
10 mg | In stock | $ 347.00 | |
25 mg | In stock | $ 589.00 | |
50 mg | In stock | $ 842.00 | |
100 mg | In stock | $ 1,160.00 | |
500 mg | In stock | $ 2,330.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 243.00 |
Description | S18-000003 is an effective orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t inhibitor (IC50: 29 nM). S18-000003 inhibits IL-17 production. |
Targets&IC50 | RORγt:29 nM |
Molecular Weight | 518.55 |
Formula | C26H25F3N2O4S |
CAS No. | 2068119-11-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (192.85 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
S18-000003 2068119-11-7 Metabolism ROR orphan aberrations acid psoriasis Inhibitor RAR-related orphan receptor retinoic receptor-related S18 000003 S-18-000003 RORγt thymic inhibit S18000003 inhibitor